Are Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Especially Useful for Cardiovascular Protection?

References

1. ↵
   Sleight P, Yusuf S. New evidence on the importance of the rennin-angiotensin system in the treatment of higher-risk patients with hypertension. J Hypertens 2003; 21: 1599–608.

   OpenUrlCrossRefPubMedWeb of Science
2. Weir MR. Effects of rennin-angiotensin system inhibition on end-organ protection: can we do better? Clin Ther 2007; 29: 1803–24.

   OpenUrl
3. Stojiljkovic L, Behnia R. Role of rennin angiotensin system inhibitors in cardiovascular and renal protection: a lesson from clinical trials. Curr Pharm Des 2007; 13: 1335–445.

   OpenUrlCrossRefPubMedWeb of Science
4. Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354: 1685–97.

   OpenUrlCrossRefPubMedWeb of Science
5. ↵
   The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545–59.

   OpenUrlCrossRefPubMedWeb of Science
6. ↵
   Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapid in patients at high risk of coronary events. N Engl J Med 2007; 357: 2109–22.

   OpenUrlCrossRefPubMedWeb of Science
7. ↵
   UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713–20.

   OpenUrlAbstract/FREE Full Text
8. ↵
   Hansson L, Lindholm LH, Niskanen L, et al. Effect of ACE inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP). Lancet 1999; 353: 611–6.

   OpenUrlCrossRefPubMedWeb of Science
9. ↵
   Hansson L, Lindholm LH, Ekbom T, et al. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension 2 (STOP- Hypertension 2) study. Lancet 1999; 354: 1751–6.

   OpenUrlCrossRefPubMedWeb of Science
10. ↵
    Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.

    OpenUrlCrossRefPubMedWeb of Science
11. ↵
    The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97.

    OpenUrlCrossRefPubMedWeb of Science
12. ↵
    Wing LMH, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin coverting enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 583–92.

    OpenUrlCrossRefPubMedWeb of Science
13. ↵
    Yui Y, Sumiyoshi T, Kodama K, et al. Comparison of nifedipine retard with angiotensin-converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res 2004; 27: 181–91.

    OpenUrlCrossRefPubMedWeb of Science
14. ↵
    Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004; 363: 2022–31.

    OpenUrlCrossRefPubMedWeb of Science
15. ↵
    UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–13.

    OpenUrlAbstract/FREE Full Text
16. ↵
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertesnive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2003; 42: 239–46.

    OpenUrlAbstract/FREE Full Text
17. ↵
    Barzilay JI, Davis BR, Bettencourt J, et al. Cardiovascular outcomes using doxazosin vs chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT Study. J Clin Hypertens 2004; 6: 116–25.

    OpenUrl
18. Whelton PK, Barzilay J, Cushman WC, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165: 1401–9.

    OpenUrlCrossRefPubMedWeb of Science
19. Rahman M, Pressel S, Davis BR, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the ALLHAT Study. Arch Inten Med 2005; 165: 936–46.

    OpenUrl
20. Wright JT, Dunn JK, Cutler JA, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 2005; 293: 1595–607.

    OpenUrlCrossRefPubMedWeb of Science
21. ↵
    Williams B. Drug treatment for hypertension: most patients will need a treatment cocktail—including a thiazide diuretic. BMJ 2003; 326: 61–2.

    OpenUrlFREE Full Text
22. Moser M. Results of ALLHAT. Is this the final answer regarding initial anti-hypertensive drug therapy? Arch Intern Med 2003; 163: 1269–73.

    OpenUrl
23. Appel LJ. The verdict from ALLHAT—Thiazide diuretics are the preferred initial therapy for hypertension. JAMA 2002; 288: 3039–42.

    OpenUrlCrossRefPubMedWeb of Science
24. Davis BR, Furberg CD, Wright JT Jr, Cutler JA, Whelton P. ALLHAT: setting the record straight. Ann Intern Med 2004; 141: 39–46.

    OpenUrlPubMedWeb of Science
25. ↵
    Shinoda E, Yui Y, Kodama K, et al. Japan Multicenter Investigation for Cardiovascular Diseases-B Study Group. Quantitative coronary angiogram analysis: nifedipine retard versus angiotensin-converting enzyme inhibitors (JMIC-B side arm study). Hypertension 2005; 45: 1153–8.

    OpenUrlAbstract/FREE Full Text
26. ↵
    The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145–53.

    OpenUrlCrossRefPubMedWeb of Science
27. ↵
    PROGRESS collaborative group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 2001; 358: 1033–41.

    OpenUrlCrossRefPubMedWeb of Science
28. ↵
    The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–88.

    OpenUrlCrossRefPubMedWeb of Science
29. ↵
    Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT Study: a randomized controlled trial. JAMA 2004; 292: 2217–26.

    OpenUrlCrossRefPubMedWeb of Science
30. ↵
    The PEACE Trial Investigators. Angiotensin-converting enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058–68.

    OpenUrlCrossRefPubMedWeb of Science
31. ↵
    Mochizuki S, Dahlof B, Shimizu M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomized, open-label, blinded end-point morbidity-mortality study. Lancet 2007; 369: 1431–9.

    OpenUrlCrossRefPubMedWeb of Science
32. ↵
    Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension 2001; 38: 28–32.

    OpenUrl
33. ↵
    Kaplan NM, Sproul LE, Mulcahy WS. Large prospective study of ramipril in patients with hypertension. CARE Investigators. Clin Ther 1993; 15: 810–8.

    OpenUrlPubMed
34. ↵
    Frampton JE, Peters DH. Ramipril. An updated review of its therapeutic use in essential hypertension and heart failure. Drugs 1995; 49: 440–66.

    OpenUrlPubMed
35. ↵
    Moutsatsos GD. More hype than HOPE. Hypertension 2003; 41: e4.

    OpenUrlPubMed
36. ↵
    Kwaku M, Burman KD, Becker KL, Mannan M. The EUROPA trial. Lancet 2003; 362: 1935.

    OpenUrlPubMed
37. ↵
    Wennberg R, Zimmermann C. The PROGRESS trial three years later: time for a balanced report of effectiveness. BMJ 2004; 329: 968–70.

    OpenUrlFREE Full Text
38. ↵
    MacMahon S, Neal B, Rodgers A, Chalmers J. The PROGRESS trial three years later: time for more action, less distraction. BMJ 2004; 329: 970–1.

    OpenUrlFREE Full Text
39. ↵
    Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 1004–10.

    OpenUrlCrossRefPubMedWeb of Science
40. ↵
    Ong HT. LIFE: lorsatan versus atenolol. Lancet 2003; 362: 1416.

    OpenUrlPubMed
41. ↵
    Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004; 364: 1684–9.

    OpenUrl
42. Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ 2006; 174: 1737–42.

    OpenUrlAbstract/FREE Full Text
43. Lindholm LH, Carlberg B, Samuelsson O. Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545–53.

    OpenUrlCrossRefPubMedWeb of Science
44. ↵
    Kjeldsen SE, Julius S, Brunner H, et al. Characteristics of 15314 hypertensive patients at high coronary risk. The VALUE Trial. Blood Press 2001; 10: 83–91.

    OpenUrlCrossRefPubMedWeb of Science
45. ↵
    Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363: 2049–51.

    OpenUrlCrossRefPubMedWeb of Science
46. ↵
    Staessen JA, Richart T. Sum and substance in the Jikei heart study. Lancet 2007; 369: 1407–8.

    OpenUrlCrossRefPubMedWeb of Science
47. ↵
    The Telmisartan Randomised Assessment Study in ACE-Intolerant Subjects with Cardiovascular Disease (TRANSCEND) investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet 2008; 372: 1174–83.

    OpenUrlCrossRefPubMedWeb of Science
48. ↵
    Yusuf S, Diener HC, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359: 1225–37.

    OpenUrlCrossRefPubMed
49. ↵
    The ONTARGET Investigators. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–59.

    OpenUrlCrossRefPubMedWeb of Science
50. ↵
    Mann JFE, Schmeider RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial. Lancet 2008; 372: 547–53.

    OpenUrlCrossRefPubMedWeb of Science
51. ↵
    Ong HT. Cardiovascular outcomes in the comparative hypertension drug trials: more consensus than controversy. Singapore Med J 2008; 49: 599–606.

    OpenUrlPubMed
52. ↵
    Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003; 289: 2560–72.

    OpenUrlCrossRefPubMedWeb of Science
53. Whitworth JA, World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983–92.

    OpenUrlCrossRefPubMedWeb of Science
54. Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004—BHS IV. J Hum Hypertens 2004; 18: 139–85.

    OpenUrlCrossRefPubMedWeb of Science
55. Mancia G, de Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension. Eur Heart J 2007; 28: 1462–536.

    OpenUrlFREE Full Text
56. ↵
    Pepine CJ. What is the optimal blood pressure and drug therapy for patients with coronary artery disease? JAMA 2004; 292: 2271–3.

    OpenUrlCrossRefPubMedWeb of Science
57. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–13.

    OpenUrlCrossRefPubMedWeb of Science
58. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345: 1291–7.

    OpenUrlCrossRefPubMedWeb of Science
59. Alder AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412–9.

    OpenUrlAbstract/FREE Full Text
60. ↵
    Daviglus ML, Liu K. Today's Agenda. We must focus on achieving favorable levels of all risk factors simultaneously. Arch Intern Med 2004; 164: 2086–7.

    OpenUrlCrossRefPubMedWeb of Science
61. ↵
    Pitt B. ACE Inhibitors for patients with vascular disease without left ventricular dysfunction—may they rest in PEACE? N Engl J Med 2004; 351: 2115–7.

    OpenUrlCrossRefPubMedWeb of Science